Daralyn Durie - Singular Genomics G Counsel
| OMIC Stock | USD 21.37 0.05 0.23% |
Insider
Daralyn Durie is G Counsel of Singular Genomics Systems
| Age | 56 |
| Address | 3010 Science Park Road, San Diego, CA, United States, 92121 |
| Phone | 858 333 7830 |
| Web | https://www.singulargenomics.com |
Singular Genomics Management Efficiency
The company has return on total asset (ROA) of (0.2427) % which means that it has lost $0.2427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5161) %, meaning that it created substantial loss on money invested by shareholders. Singular Genomics' management efficiency ratios could be used to measure how well Singular Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.44. At present, Singular Genomics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.2 M, whereas Total Assets are forecasted to decline to about 226.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lakshmanan Kannappan | Healthcare Triangle | 57 | |
| Elizabeth Hall | Nutex Health | N/A | |
| FACC MD | Heartbeam | 65 | |
| John Lorbiecki | Aclarion | 61 | |
| LaChoenda Rosales | Nutex Health | N/A | |
| MD MBA | Nutex Health | 51 | |
| Daniel Tan | EUDA Health Holdings | 43 | |
| Jon Hunt | Heartbeam | 68 | |
| Wei Chen | EUDA Health Holdings | 39 | |
| BSN JD | Nutex Health | N/A | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| Ryan Bond | Aclarion | 52 | |
| Branislav Vajdic | Heartbeam | 69 | |
| Denise Pufal | Nutex Health | N/A | |
| Suresh Venkatachari | Healthcare Triangle | 57 | |
| Sudish Mogli | Healthcare Triangle | 55 | |
| Thyagarajan Ramachandran | Healthcare Triangle | 48 | |
| Kristi Lane | Healthcare Triangle | N/A | |
| Michael Gill | Healthcare Triangle | 46 | |
| Vivian MBA | Nutex Health | N/A | |
| Ken Persen | Heartbeam | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.24 |
Singular Genomics Systems Leadership Team
Elected by the shareholders, the Singular Genomics' board of directors comprises two types of representatives: Singular Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Singular. The board's role is to monitor Singular Genomics' management team and ensure that shareholders' interests are well served. Singular Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Singular Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Stier, General VP | ||
| Daralyn Durie, G Counsel | ||
| Samuel Ropp, Chief Officer | ||
| Andrew Spaventa, CEO, Founder | ||
| Eli Glezer, Chief Founder | ||
| Dalen Meeter, Chief Officer | ||
| Jeff Bullard, Head Sales | ||
| MBA Velarde, Senior Strategy | ||
| Vincent Brancaccio, Head Resources | ||
| Jyotsna Ghai, Chief Officer | ||
| David Barker, Member Founder |
Singular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Singular Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (30.94) % | ||||
| Current Valuation | (9.66 M) | ||||
| Shares Outstanding | 2.51 M | ||||
| Shares Owned By Insiders | 13.90 % | ||||
| Shares Owned By Institutions | 60.22 % | ||||
| Number Of Shares Shorted | 71.17 K | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.